GSK Consumer Healthcare and FLONASE® Sensimist™ Allergy Relief, along with Emmy® Award-winning choreographer and entertainer Derek Hough, today announced the launch of the 2017 Greater American Road Trip featuring social media’s favorite family, the Eh Bees. On Thursday, March 16, the Eh Bee family will begin their coast-to-coast journey to rethink allergy treatment and leave each city a little bit greater than they found it.
Derek, along with Eh Bee family members Mama Bee and her son Mr. Monkey, all suffer from allergies, but are determined to be greater than their itchy, watery eyesi and congested noses with the help of new FLONASE Sensimist. After kicking off the journey together in Los Angeles, Derek will challenge the Eh Bees and their allergies as they partner with local organizations throughout some of the worst allergy cities in the country.
To view the multimedia release go to:
https://www.multivu.com/players/English/8061451-flonase-greater-american-road-trip-derek-hough-eh-bee/
See America, Allergan’s initiative to fight against preventable blindness in the United States, today unveiled a powerful video featuring award-winning actor and hip-hop artist Common, that urges Americans to “stand in the way of darkness”.
The video harnesses Common’s striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss, and challenges us all to imagine a life without sight.
“I'm proud to join Allergan in the fight against preventable blindness,” said Common. “Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8057551-common-joins-allergan-see-america-against-preventable-blindness/
With the tap of the JOIFUL app, consumers in the Los Angeles area can enjoy mobile salon and spa treatments in the comfort of their home, office or hotel. Beauty industry Artists are at the ready to provide a suite of beauty and wellness treatments including: blowouts; hair styling; men’s haircuts and hot shaves; a variety of massage options; facials; manicures/pedicures as well as specialty services like waxing treatments.
JOIFUL was created to make routine beauty services accessible to time-compressed people who often skip these rituals due to their busy schedules. It’s the only on-demand beauty app with a full suite of salon and spa services – with no look books to limit personal style. Mobile beauty customers can book their treatment, track their Artist in transit and pay with credit card or Apple Pay. Artists will arrive in 60 minutes and gratuity is included in the affordable luxury pricing.
To view the multimedia release go to:
http://www.multivu.com/players/English/8026051-joiful-on-demand-beauty-and-wellness-app/
LUNGevity, the nation’s leading lung cancer-focused nonprofit organization today launched a new mobile application designed to make understanding and living with lung cancer less daunting and considerably more manageable. The new Lung Cancer Navigator mobile app provides lung cancer patients with access to the latest medical and treatment information related to their specific lung cancer diagnosis, and serves as a convenient hub for organizing customized care and support networks, asking questions, describing and tracking symptoms, and managing multiple medications.
To view the multimedia release go to:
http://www.multivu.com/players/English/7865551-lungevity-lung-cancer-navigator-app/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Today, WebMD released The Cutting Edge of Cancer a five-part investigative video series developed in partnership with Robin Roberts and her independent production company, Rock’n Robin Productions. Through compelling patient stories and insights from medical experts, The Cutting Edge of Cancer, supported by Cancer Treatment Centers of America®, highlights some of the most promising areas of medical innovation in cancer care, including early detection, immunotherapy, genomic research, and integrative medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579755-webmd-robin-roberts-cutting-edge-of-cancer/
Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme.
Ten years ago, a child in Sub-Saharan Africa diagnosed with type 1 diabetes often had a life expectancy of less than a year1. In response, Novo Nordisk established the Changing Diabetes® in Children programme to support sustainable quality care and improved diagnosis of the condition. Since the start of the programme in 2009, 13,700 children in nine countries in Africa and South-East Asia have received free human insulin and access to diabetes care.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
DePuy Synthes Companies today announced the launch of Hit Play, an educational initiative that encourages those dealing with hip or knee pain to stop settling for a life on ‘pause’ and instead take action to get back to the activities and people they love most.
Osteoarthritis is one of the most common reasons for severe hip or knee pain, affecting nearly 27 million Americans today and will potentially affect up to 67 million people by 2030.1,2 In turn, demand for hip and knee replacements are expected to dramatically increase, yet many women see joint replacement as a “last resort” and often wait until the pain has become unbearable before turning to surgery. Through a series of compelling and relatable content, DePuy Synthes seeks to inspire the millions of people stuck on ‘pause’ due to hip or knee pain to explore joint replacement with a doctor, as a potential viable solution when they Hit Play.
To view the multimedia release go to:
http://www.multivu.com/players/English/79644241-lysol-madison-square-bgca-expose-germs/
Every 23 seconds, someone in the United States is diagnosed with diabetes. It's estimated that one in 11 Americans has the disease—more than 29 million people—and another 86 million have prediabetes and are at risk for developing type 2 diabetes. The numbers alone are staggering, and the people affected by the disease include those who have diabetes and their friends, family, caregivers and communities.
American Diabetes Month®, observed by the American Diabetes Association® (Association) every November, is a time to focus the nation's attention on the many people who are affected by diabetes and to raise the urgency about the need to address diabetes. To help spark a national conversation, the Association is asking people to share their stories about what it truly means to live with diabetes with a new campaign, This Is Diabetes™.
To view the multimedia release go to:
http://www.multivu.com/players/English/7711431-american-diabetes-month-thisisdiabetes/
Ethicon* joins world-renowned experts in bariatric surgery to share the latest breakthroughs in science and innovation that are advancing surgery in the fight against obesity and metabolic diseases during ObesityWeek 2016, the combined annual meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS). Ethicon will highlight the growing body of research and evidence on the benefits of bariatric surgery, a new sleeve gastrectomy training module on the Touch Surgery app, and its comprehensive portfolio of bariatric surgery products aimed to improve patient outcomes.
“Ethicon’s mission is to lead the way in resolving the burden of obesity for both patients and healthcare systems by expanding access to care and demonstrating the critical value of treatment through research and evidence, while also enabling new technologies,” said Dr. Elliott Fegelman, Therapeutic Area Expert, Metabolics, Johnson & Johnson Innovation.
To view the multimedia release go to:
http://www.multivu.com/players/English/7965651-ethicon-bariatric-surgery-access-obesity-week-2016/
Don’t trust us, trust Science: Abbott is among the best science-based companies to work for in the world.
For the 13th consecutive year, the journal Science today recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
”Abbott is unique in that we’ve been adding to our reservoir of scientific knowledge for 128 years,“ said John Frels, Ph.D., chair of Abbott’s Scientific Governing Board, which oversees the company’s senior scientific career track. ”We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people’s lives.“
To view the multimedia release go to:
http://www.multivu.com/players/English/7962251-science-names-abbott-2016-top-employer/
